Fresita Proteins sets Rs 89.759 crore 5-for-6 rights issue
Key highlights
- Fresita Proteins plans to issue up to 74,79,917 rights shares at Rs 120 each for up to Rs 89.759 crore.
- Fresita Proteins has set the entitlement at 5 rights shares for every 6 shares held on October 30, 2026.
- Fresita Proteins will open the rights issue on November 12, 2026 and close it on November 26, 2026.
- Fresita Proteins has set November 20, 2026 as the last date for on-market renunciation.
powered by IRIS

Fresita Proteins Limited plans to raise up to Rs 89.759 crore through a rights issue of up to 74,79,917 shares at Rs 120 each, opening on November 12, 2026, for shareholders eligible under the October 30 record date. The offer gives five new shares for every six fully paid shares held and closes on November 26, 2026.
Know FRESITA PROTEINS inside out
Results, valuation, peers and who's buying, in one view.
What are Fresita Proteins' rights issue terms?
Fresita Proteins is offering up to 74,79,917 fully paid equity shares with a face value of Rs 10 each at an issue price of Rs 120 per share. The Rs 120 price comprises Rs 10 face value and Rs 110 securities premium, while the maximum issue size is Rs 89.759 crore, assuming full subscription and subject to the final basis of allotment.
The entitlement is five rights shares for every six fully paid equity shares held on the record date of October 30, 2026. An investor holding 600 eligible shares would therefore receive an entitlement for 500 rights shares, requiring Rs 60,000 to subscribe to that entitlement at Rs 120 a share.
The issue price is 12 times the Rs 10 face value, as stated in the offer advertisement. The Rs 110 premium is Rs 100 higher than face value, showing that most of the Rs 120 subscription amount is premium rather than share capital. Fresita Proteins identifies Onix Renewable Limited as its promoter.
Fresita Proteins describes the Rs 89.759 crore figure as an aggregate maximum, not an assured amount of funds raised. The advertisement says the proposed issue remains subject to requisite approvals, market conditions and other considerations, and it does not disclose the intended use or allocation of the proceeds.
When can Fresita Proteins shareholders subscribe or transfer rights?
Fresita Proteins will open the issue on November 12, 2026 and close it on November 26, 2026. The last date for on-market renunciation is November 20, 2026, giving eligible holders eight calendar days from opening to transfer rights through the stock exchange platform.
The board or its rights issue committee can extend the issue period, but the filing limits the total period to 30 days from the opening date, inclusive of November 12. The company also states that an applicant cannot withdraw an application after the issue closing date of November 26.
Eligible shareholders can renounce rights entitlements in full or in part through either on-market or off-market transfer. For an off-market transfer, the entitlement must reach the renouncee's demat account on or before November 26, and the recipient must then separately apply for the rights shares.
An entitlement alone does not result in allotment. Fresita Proteins says that if an eligible holder or renouncee does not apply by the closing date, the entitlement will lapse and be extinguished; no shares will be credited even if the entitlement was bought in the market or transferred off-market.
How could the 5-for-6 issue change Fresita Proteins shareholding?
Fresita Proteins' 5-for-6 structure adds five potential new shares for every six existing eligible shares. On an illustrative base of six existing shares, full issuance would take the total to 11 shares, an increase of 83.33% from the original six-share base.
A shareholder who takes up the full five-share entitlement would hold 11 shares after the illustrative issue, matching the expanded base proportionally. A shareholder who retained only the original six shares while all available rights were issued would hold six out of 11 shares, or 54.55% of the former proportional position; this is arithmetic based on the disclosed ratio, not a Fresita Proteins forecast.
The offer permits applications for additional rights shares where an investor has applied for the full entitlement. However, the advertisement says the issue is subject to finalisation of the basis of allotment, so it does not establish how many additional shares, if any, an applicant may receive.
The rights shares are proposed to be listed on BSE Limited after allotment. Fresita Proteins says BSE gave in-principle approval for listing the rights shares on October 8, 2026, while the start of trading after allotment will remain at the exchange's discretion under applicable law.
Got a follow-up? Ask IRIS
How must Fresita Proteins investors apply for the rights shares?
Fresita Proteins requires applicants to use Application Supported by Blocked Amount, or ASBA, for the November 12 to November 26 issue. Under ASBA, an investor authorises a self-certified syndicate bank, or SCSB, to block the application amount in an ASBA-enabled bank account rather than paying by cheque.
An applicant must authorise a block for the full amount sought at Rs 120 per rights share. On November 26, ASBA applications will be uploaded until 5:00 p.m. Indian Standard Time, unless the stock exchange permits an extended time, according to the advertisement.
Applications may be made at a designated SCSB branch using a physical form or electronically through an SCSB's website where that facility is available. Fresita Proteins says an application may be treated as declined if the form is not submitted or uploaded and the application money is not blocked with the SCSB by the closing deadline.
An eligible shareholder in India who has not received an application form may submit a plain-paper application through ASBA, subject to the prescribed details and an Indian address. A plain-paper applicant cannot renounce the rights entitlement, and submitting both a form and a plain-paper application for rights credited to the same demat account may lead to rejection.
What must Fresita Proteins physical shareholders and renouncees do?
Fresita Proteins will credit rights entitlements and allot rights shares only in dematerialised form. A shareholder holding physical shares on October 30, 2026 must provide demat-account details to the registrar or Fresita Proteins at least two clear working days before the November 26 closing date.
The company says this timing is intended to allow the entitlement to be credited at least one day before the issue closes. A physical shareholder who does not provide demat details by the specified deadline will not be able to apply against rights relating to those physical holdings, and the entitlement will lapse.
Allotted rights shares will be credited to the same depository account in which an investor held Fresita Proteins equity shares on the record date. Rights entitlements are intended to be admitted for trading under International Securities Identification Number INE995U20011, subject to requisite approvals.
Fresita Proteins says entitlements relating to frozen or suspended demat accounts, disputed ownership, failed credits, certain suspense-account holdings and Investor Education and Protection Fund holdings may be placed in a company escrow demat account. The company asks affected holders to provide supporting account and ownership details at least two working days before the closing date so transfers can be processed before November 26.
Conclusion
Fresita Proteins has specified a maximum Rs 89.759 crore raise through up to 74,79,917 shares priced at Rs 120, with a 5-for-6 entitlement based on holdings as of October 30, 2026. The ratio would materially expand the share base if fully subscribed, while applications, entitlements and allotments are structured around dematerialised holdings and the ASBA process.
The dates to watch are the November 12 opening, the November 20 deadline for on-market renunciation and the November 26 closing date. Fresita Proteins says its board or rights issue committee may extend the offer, within a 30-day limit from opening, and that final allotment remains subject to the basis of allotment and subsequent BSE trading commencement.


